The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the CTAF process, and find out how topics are selected.
CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the CTAF Panel must meet ICER’s criteria for Conflict of Interest.
For CTAF reports published prior to September 2013, please email email@example.com
The box below provides information on the topic of the next meeting of CTAF. For more information about past and other upcoming meetings, see the box to the right.
LA Renaissance Airport Hotel
9620 Airport Blvd
Los Angeles, CA 90045
CTAF will convene to review ICER's report on CGRP inhibitors for prevention of migraine headaches.
To watch the live webcast, beginning at 10am PT, visit http://www.beaconliveweb.com/join?jrd=aWNlcjJ8OTc5Nzk3fElDRVJ8QXR0ZW5kZWV8IHwgfA
Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.
Interventions of interest, July 2018 review:
- Erenumab (Amgen/Novartis)
- Fremanezumab (Teva)
- Galcanezumab (Eli Lilly)
Interventions of interest, July 2014 review:
- OnabotulinumtoxinA (Botox®, Allergan, Inc)
- Transcutaneous electrical nerve stimulation (Cefaly®, Cefaly Technology)
- Single pulse transcranial magnetic stimulation (SpringTMS™, eNeura Inc.)